Lipocine to host virtual KOL event on LPCN 1154 for postpartum depression on June 12, 2026

Lipocine Inc.

Virtual KOL event focused on unmet needs in postpartum depression and clinical profile of LPCN 1154 (oral brexanolone).
Event scheduled for June 12, 2026 at 11:00 AM ET; advance registration required.
LPCN 1154 Phase 3 trial showed efficacy in subgroup analysis excluding outlier site; 100% dosing completion.
PPD affects ~1 in 5 U.S. women; annual economic burden estimated at $14.2 billion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.